EU Science Hub

PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control

Abstract: 
To evaluate the potential of 225Ac-PSMA617 for PSMA-targeting alpha-therapy of poor-prognosis advanced-stage mCRPC patients.